Kostas Biliouris
Stock Analyst at BMO Capital
(1.17)
# 3,779
Out of 5,090 analysts
62
Total ratings
36.73%
Success rate
-14.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $22.04 | +126.86% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $456.60 | +2.93% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $81.21 | -13.80% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.74 | +129.89% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.31 | +141.69% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $71.75 | +0.36% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $20.50 | +143.90% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.93 | +260.75% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.45 | +429.10% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $4.94 | +588.26% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $29.65 | +18.04% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.78 | +857.75% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $10.93 | +265.97% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $28.14 | +219.83% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $6.96 | +1,624.14% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $27.44 | +107.73% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $73.15 | -49.42% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $53.01 | +88.64% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.75 | +407.34% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $56.50 | +73.45% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $22.04
Upside: +126.86%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $456.60
Upside: +2.93%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $81.21
Upside: -13.80%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.74
Upside: +129.89%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.31
Upside: +141.69%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $71.75
Upside: +0.36%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $20.50
Upside: +143.90%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.93
Upside: +260.75%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.45
Upside: +429.10%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.94
Upside: +588.26%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $29.65
Upside: +18.04%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.78
Upside: +857.75%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $10.93
Upside: +265.97%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $28.14
Upside: +219.83%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $6.96
Upside: +1,624.14%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $27.44
Upside: +107.73%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $73.15
Upside: -49.42%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $53.01
Upside: +88.64%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.75
Upside: +407.34%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $56.50
Upside: +73.45%